PDT Partners LLC Invests $2.81 Million in Keros Therapeutics, Inc. $KROS

Key Points

• PDT Partners LLC has made a new investment of approximately $2.81 million in Keros Therapeutics, purchasing 276,060 shares during the first quarter.
• Keros Therapeutics reported a quarterly earnings per share (EPS) of ($0.76), which beat the consensus estimate of ($1.14), but achieved only $0.02 million in revenue compared to an expected $3.83 million.
• Seven research analysts currently rate Keros Therapeutics stock as a "Moderate Buy" with an average price target of $30.00.

PDT Partners LLC bought a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 276,060 shares of the company's stock, valued at approximately $2,813,000. PDT Partners LLC owned about 0.68% of Keros Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in KROS. FNY Investment Advisers LLC bought a new position in Keros Therapeutics during the first quarter worth about $25,000. CWM LLC grew its stake in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after buying an additional 2,641 shares in the last quarter. Entropy Technologies LP bought a new position in shares of Keros Therapeutics during the 1st quarter worth approximately $121,000. AlphaQuest LLC increased its stake in shares of Keros Therapeutics by 268.0% during the first quarter. AlphaQuest LLC now owns 13,234 shares of the company's stock worth $135,000 after purchasing an additional 9,638 shares during the period. Finally, Corebridge Financial Inc. increased its stake in Keros Therapeutics by 6.4% in the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company's stock valued at $165,000 after acquiring an additional 972 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Performance

NASDAQ KROS traded up $0.04 during mid-day trading on Friday, reaching $15.59. 537,578 shares of the stock were exchanged, compared to its average volume of 472,423. The company has a market capitalization of $633.19 million, a P/E ratio of 50.29, a P/E/G ratio of 2.01 and a beta of 1.06. The business's 50 day moving average is $14.39 and its 200-day moving average is $13.33. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $3.83 million. During the same quarter last year, the business posted ($1.25) earnings per share. The firm's revenue was up 49002.7% compared to the same quarter last year. Equities analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Bank of America downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank cut their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Wedbush reiterated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, HC Wainwright reduced their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating for the company in a report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.